Compare Merck & Co., Inc. (MRK) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs TORM plc — how do they compare? Merck & Co., Inc. trades at $145.72 (market cap $351.28B), while TORM plc trades at $40.37 (market cap $4.12B). The key difference: Merck & Co., Inc. is far larger — about 85.3× TORM plc's market cap, and TORM plc pays the higher dividend (11.03%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and TORM plc for 23 Days on average.
| MRK | TRMD | |
|---|---|---|
Market Cap | $351.28B | $4.12B |
Volume | 7,969,665 | 2,863,116 |
Sector | Health | Industrials |
52-Week High | $156.43 | $41.05 |
52-Week Low | $82.49 | $19.39 |
Typical Hold Time | 98 Days | 23 Days |
Enterprise Value | $398.04B | $4.83B |
Dividend Yield | 2.39% | 11.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
TRMD trades at $40.54, up 4.16% today, with a bullish technical signal from moving averages and strong profitability metrics including a 35.52% net income margin and 26.84% ROE. Recent earnings showed a Q2 2026 miss but a Q4 2025 beat, while 2026 revenue is projected to grow to $1.8B. A $2.40 dividend is scheduled for September 2026, and analyst consensus is unanimously bullish with 3 buy ratings.
The outlook is positive given robust fundamentals and analyst support, but risks include spot rate volatility in the tanker market and recent insider selling. Upside potential hinges on sustained freight rates, while a downturn could pressure earnings. The stock presents a value opportunity with a low P/E of 6.59, though cyclical industry exposure warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
